Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 88.18B |
| Revenue (ttm) | 44.07B |
| Net Income (ttm) | 5.01B |
| Shares Out | n/a |
| EPS (ttm) | 2.47 |
| PE Ratio | 17.59 |
| Forward PE | 7.30 |
| Dividend | 2.26 (5.34%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 1,175 |
| Average Volume | 1,687 |
| Open | 43.20 |
| Previous Close | 42.85 |
| Day's Range | 43.15 - 43.22 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.40 |
| RSI | 39.11 |
| Earnings Date | Apr 24, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
Looking into the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) shares are trading at $47.05, after a 1.20% decrease. Over the past month, the stock decreased by 6.76% , but over the past yea...
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 mil...
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (...
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ: CYTK) aficam...
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates
Trump pharma tariffs would raise U.S. drug costs by $51 billion annually, report finds
Pharmaceutical Research and Manufacturers of America includes Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, among others.
5 Positives From Bristol-Myers Squibb's Q1 2025 Results
Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance
S&P 500 Rallies 2% On Nvidia, Tesla Gains — But Market Mood Stuck In 'Fear'
The CNN Money Fear and Greed index some improvement in market sentiment, while the index remained in the “Fear” zone on Thursday. U.S. stocks settled higher on Thursday, with the Dow Jones index jumpi...
Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday. The Dow traded up 0.97% to 39,989.57 while the NASDAQ gained 2.24% to 17,082.79. The S&P 5...
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure Ltd (NASDAQ: NVCR) reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents . Sales increased 12% year over year...
Bristol Myers Squibb raises 2025 EPS guidance to $6.70-$7.00 amid strong growth portfolio performance
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsChuck Triano - SVP and Head of IRChris...
Bristol-Myers Squibb Is A Good Pick
Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here to find out why BMY stock is a Buy.
Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates
Bristol Myers Squibb stock dropped Thursday, though the drugmaker beat first-quarter expectations and raised its outlook for the year.
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year. The biotechnology company’s revenues declined 6% in Q1. Net income […] The post Bristo...
Bristol-Myers Squibb Company 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q1 earnings call.
The USD is lower to start the new trading day vs the EURUSD, USDJPY and GBPUSD.
The USD is lower vs. the 3 major currency pairs a day after a run lower after Pres. Trump and his administration threw out trial balloons that tariffs vs China would not be sustained and that other de...
Bristol-Myers gains as forex tailwinds prompt guidance raise
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.